Suppr超能文献

载表柔比星DC微球™与不同非离子型造影剂的相容性。

Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media.

作者信息

Sarakbi Iman, Krämer Irene

机构信息

Department of Pharmacy, University Medical Center Mainz, Johannes Gutenberg-University, Langenbeckstraße, Mainz, Germany.

Department of Pharmacy, University Medical Center Mainz, Johannes Gutenberg-University, Langenbeckstraße, Mainz, Germany

出版信息

J Oncol Pharm Pract. 2016 Dec;22(6):749-756. doi: 10.1177/1078155215607088. Epub 2015 Oct 1.

Abstract

PURPOSE

The aim of this study was to determine the compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media over a period of seven days when stored light protected under refrigerated conditions.

METHODS

DC bead™ (2 ml) (Biocompatibles UK Ltd) of the bead size 70-150 µm ( = DC bead M1) or bead size 100-300 µm were loaded with 75 mg epirubicin powder formulation (Farmorubicin® dissolved in 3 ml water for injection to a concentration of 25 mg/ml) or 76 mg epirubicin injection solution (Epimedac® 2 mg/ml) within 2 h or 6 h, respectively. After removal of the excess solution, the epirubicin-loaded beads were mixed in polypropylene syringes with an equal volume (∼1.5 ml) of contrast media, i.e. Accupaque™ 300 (Nycomed Inc.), Imeron® 300 (Bracco S.p.A), Ultravist® 300 (Bayer Pharma AG), Visipaque™ 320 (GE Healthcare) and agitated in a controlled manner to get a homogenous suspension. Syringes with loaded beads in contrast media were stored protected from light under refrigeration (2-8℃). Compatibility was determined by measuring epirubicin concentrations in the suspensions in triplicate on day 0, 1, and 7. A reversed phase high-performance liquid chromatography assay with ultraviolet detection was utilized to analyze the concentration and purity of epirubicin.

RESULTS

Mixing of epirubicin-loaded beads with different non-ionic contrast media released 0.1-0.5% of epirubicin over a period of 24 h, irrespectively, of the DC bead™ size or type of contrast media. No further elution or degradation was observed after seven days when the admixtures were stored protected from light under refrigeration.

CONCLUSION

Compatibility of epirubicin-loaded DC bead™ with an equal volume of different contrast media in polypropylene syringes is given over a period of seven days. Due to a maximum elution of 0.1-0.5% of epirubicin from loaded DC bead™, admixtures with contrast media can be prepared in advance in centralized cytotoxic preparation units. Microbiological aspects have to be considered when determining the expiration date of the product.

摘要

目的

本研究的目的是确定在冷藏条件下避光储存7天期间,载有表柔比星的DC bead™与不同非离子型造影剂的相容性。

方法

将粒径为70 - 150 µm的DC bead™(2 ml)(英国生物相容性公司)或粒径为100 - 300 µm的DC bead™分别在2小时或6小时内装载75 mg表柔比星粉剂(将法玛新®溶解于3 ml注射用水中配制成浓度为25 mg/ml)或76 mg表柔比星注射液(表柔比星®2 mg/ml)。去除多余溶液后,将载有表柔比星的微球在聚丙烯注射器中与等体积(约1.5 ml)的造影剂混合,即碘克沙醇™300(奈科明公司)、碘美普尔®300(博莱科公司)、优维显®300(拜耳医药保健公司)、威视派克™320(通用电气医疗集团),并以可控方式搅拌以获得均匀悬浮液。装有微球与造影剂混合物的注射器在冷藏(2 - 8℃)且避光条件下储存。通过在第0天、第1天和第7天对悬浮液中的表柔比星浓度进行一式三份测量来确定相容性。采用带紫外检测的反相高效液相色谱法分析表柔比星的浓度和纯度。

结果

载有表柔比星的微球与不同非离子型造影剂混合,在24小时内释放0.1 - 0.5%的表柔比星,与DC bead™的粒径或造影剂类型无关。当混合物在冷藏且避光条件下储存7天后,未观察到进一步的洗脱或降解。

结论

载有表柔比星的DC bead™与聚丙烯注射器中等体积的不同造影剂在7天内具有相容性。由于载有表柔比星的DC bead™中表柔比星的最大洗脱量为0.1 - 0.5%,可在集中细胞毒性制剂制备单元中提前制备与造影剂的混合物。在确定产品有效期时必须考虑微生物学方面的因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验